DRUG STOCKS SLIP; DISCOVERY PLUNGES ON DRUG DELAY

Drug stocks slipped into negative territory early Wednesday as Discovery Laboratories plunged on news that the FDA still won't approve its pediatric treatment Surfaxin.
Investors Business Daily